El vaccí de Sanofi-GSK contra la COVID-19 també coneguda com VAT00002 és un vaccí contra la COVID-19, candidat, desenvolupat per Sanofi Pasteur i GSK.[1][2][3]
Referències
- ↑ «Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older». United States National Library of Medicine.
- ↑ «Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)». United States National Library of Medicine.
- ↑ «Study of Recombinant Protein Vaccine with Adjuvant against COVID-19 in Adults 18 Years of Age and Older.». Pan African Clinical Trials Registry.
|
|---|
SARS-CoV-2 |
|---|
- El virus
- Variants del virus
|
|
|
Als Països Catalans |
|---|
| Aplicacions/actuacions | |
|---|
| Afectació per territoris | |
|---|
|
|
|
|
